Brief Summary
Multi-center, observational, U.S.-based longitudinal program. Data will be collected prospectively for 3 years. Individual physician feedback will be provided on data collected with the purpose of improving the management of patients - quality enhancement research initiative (QuERI) process from adult patients enrolled with a history of repaired Congenital Heart Disease (CHD).
Brief Title
Adult Congenital Heart Disease Registry (QuERI)
Detailed Description
Approximately 800 male and female adult patients with a history of repaired CHD will be recruited from approximately 100 cardiology practices and will be followed up every twelve months for the period of three years. Consecutive patients in each practice meeting inclusion and exclusion criteria should be considered for the study. Two groups of subjects will be enrolled based on identical exclusion criteria and inclusion criteria, with the exception only of inclusion criteria #3: cohort 1- those demonstrating historic high risk criteria and cohort 2 - those demonstrating current high risk criteria.
Categories
Completion Date
Completion Date Type
Actual
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Inclusion Criteria: Cohort 1 (historic high risk)
1. Male and female adults (≥ 18 years of age)
2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)
3. History of a large defect prior to closure as evidenced by any one of the following:
* Size of: ASD \> 2 cm; VSD \> 1 cm; PDA \> 0.6 cm
* Shunt 2:1 or greater
* Pre-operative PH (PAS \> 40 mmHg) or documented shunt- related heart failure (radiographic evidence)
* Pre-operative atrial fibrillation or flutter
4. High risk features (any one the following):
* Age \> 40 years
* Later surgical repair:
i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD
* Sinus venosus defect
* Primum defect
* WHO functional class \> 1
* Atrial fibrillation or flutter
5. Echocardiographic evidence of high risk features. Any one of the following:
* Degree of TR that is mild or greater
* Right ventricular (RV) systolic dysfunction
* Evidence of RV dilatation: Any one of the following:
i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter \> 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole \> 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)
* Any abnormality in the motion of the inter-ventricular septum
6. Ability and desire to execute the consent for follow up
Inclusion Criteria: Cohort 2 (current high risk)
1. Male and female adults (≥ 18 years of age)
2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)
3. Current (within the last 12 months) evidence of 1 or more of the 7 following criteria:
* Desaturation on exercise (92% or less)
* 6 MWD \<380 m
* PFT demonstrating DLC \<70% predicted \& FEV1\>70% predicted
* ECG demonstrating i) RAD and ii) RVH or RAE
* Physical findings of edema accompanied by elevated JVP and +HJR
* CXR evidence of enlarged main and/or hilar pulmonary arterial shadows in association with right ventricular enlargement
* Elevated biomarks (BNP or NT-proBNP above upper limit of normal)
4. High risk features (any one of the following:)
* Age \> 40 years
* Later surgical repair:
i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD
* Sinus venosus defect
* Primum defect
* WHO functional class \> 1
* Atrial fibrillation or flutter
5. Echocardiographic evidence of high risk features. Any one of the following:
* Degree of TR that is mild or greater
* Right ventricular (RV) systolic dysfunction
* Evidence of RV dilatation: Any one of the following:
i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter \> 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole \> 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)
* Any abnormality in the motion of the inter-ventricular septum
6. Ability and desire to execute the consent for follow up
Exclusion Criteria:
1. Poor mental function, drug or substance (e.g., alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study
2. Diagnosis of PAH (defined as RHC demonstrating mPAP ≥ 25 mm Hg and PCWP ≤ 15 and PVR \> 3 WU or PVR (indexed) \> 4 WU or treatment with PAH specific therapy) after surgical repair and prior to visit 1
3. Prior inclusion in this registry
1. Male and female adults (≥ 18 years of age)
2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)
3. History of a large defect prior to closure as evidenced by any one of the following:
* Size of: ASD \> 2 cm; VSD \> 1 cm; PDA \> 0.6 cm
* Shunt 2:1 or greater
* Pre-operative PH (PAS \> 40 mmHg) or documented shunt- related heart failure (radiographic evidence)
* Pre-operative atrial fibrillation or flutter
4. High risk features (any one the following):
* Age \> 40 years
* Later surgical repair:
i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD
* Sinus venosus defect
* Primum defect
* WHO functional class \> 1
* Atrial fibrillation or flutter
5. Echocardiographic evidence of high risk features. Any one of the following:
* Degree of TR that is mild or greater
* Right ventricular (RV) systolic dysfunction
* Evidence of RV dilatation: Any one of the following:
i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter \> 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole \> 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)
* Any abnormality in the motion of the inter-ventricular septum
6. Ability and desire to execute the consent for follow up
Inclusion Criteria: Cohort 2 (current high risk)
1. Male and female adults (≥ 18 years of age)
2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)
3. Current (within the last 12 months) evidence of 1 or more of the 7 following criteria:
* Desaturation on exercise (92% or less)
* 6 MWD \<380 m
* PFT demonstrating DLC \<70% predicted \& FEV1\>70% predicted
* ECG demonstrating i) RAD and ii) RVH or RAE
* Physical findings of edema accompanied by elevated JVP and +HJR
* CXR evidence of enlarged main and/or hilar pulmonary arterial shadows in association with right ventricular enlargement
* Elevated biomarks (BNP or NT-proBNP above upper limit of normal)
4. High risk features (any one of the following:)
* Age \> 40 years
* Later surgical repair:
i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD
* Sinus venosus defect
* Primum defect
* WHO functional class \> 1
* Atrial fibrillation or flutter
5. Echocardiographic evidence of high risk features. Any one of the following:
* Degree of TR that is mild or greater
* Right ventricular (RV) systolic dysfunction
* Evidence of RV dilatation: Any one of the following:
i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter \> 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole \> 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)
* Any abnormality in the motion of the inter-ventricular septum
6. Ability and desire to execute the consent for follow up
Exclusion Criteria:
1. Poor mental function, drug or substance (e.g., alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study
2. Diagnosis of PAH (defined as RHC demonstrating mPAP ≥ 25 mm Hg and PCWP ≤ 15 and PVR \> 3 WU or PVR (indexed) \> 4 WU or treatment with PAH specific therapy) after surgical repair and prior to visit 1
3. Prior inclusion in this registry
Inclusion Criteria
Inclusion Criteria: Cohort 1 (historic high risk)
1. Male and female adults (≥ 18 years of age)
2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)
3. History of a large defect prior to closure as evidenced by any one of the following:
* Size of: ASD \> 2 cm; VSD \> 1 cm; PDA \> 0.6 cm
* Shunt 2:1 or greater
* Pre-operative PH (PAS \> 40 mmHg) or documented shunt- related heart failure (radiographic evidence)
* Pre-operative atrial fibrillation or flutter
4. High risk features (any one the following):
* Age \> 40 years
* Later surgical repair:
i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD
* Sinus venosus defect
* Primum defect
* WHO functional class \> 1
* Atrial fibrillation or flutter
5. Echocardiographic evidence of high risk features. Any one of the following:
* Degree of TR that is mild or greater
* Right ventricular (RV) systolic dysfunction
* Evidence of RV dilatation: Any one of the following:
i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter \> 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole \> 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)
* Any abnormality in the motion of the inter-ventricular septum
6. Ability and desire to execute the consent for follow up
Inclusion Criteria: Cohort 2 (current high risk)
1. Male and female adults (≥ 18 years of age)
2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)
3. Current (within the last 12 months) evidence of 1 or more of the 7 following criteria:
* Desaturation on exercise (92% or less)
* 6 MWD \<380 m
* PFT demonstrating DLC \<70% predicted \& FEV1\>70% predicted
* ECG demonstrating i) RAD and ii) RVH or RAE
* Physical findings of edema accompanied by elevated JVP and +HJR
* CXR evidence of enlarged main and/or hilar pulmonary arterial shadows in association with right ventricular enlargement
* Elevated biomarks (BNP or NT-proBNP above upper limit of normal)
4. High risk features (any one of the following:)
* Age \> 40 years
* Later surgical repair:
i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD
* Sinus venosus defect
* Primum defect
* WHO functional class \> 1
* Atrial fibrillation or flutter
5. Echocardiographic evidence of high risk features. Any one of the following:
* Degree of TR that is mild or greater
* Right ventricular (RV) systolic dysfunction
* Evidence of RV dilatation: Any one of the following:
i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter \> 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole \> 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)
* Any abnormality in the motion of the inter-ventricular septum
6. Ability and desire to execute the consent for follow up
1. Male and female adults (≥ 18 years of age)
2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)
3. History of a large defect prior to closure as evidenced by any one of the following:
* Size of: ASD \> 2 cm; VSD \> 1 cm; PDA \> 0.6 cm
* Shunt 2:1 or greater
* Pre-operative PH (PAS \> 40 mmHg) or documented shunt- related heart failure (radiographic evidence)
* Pre-operative atrial fibrillation or flutter
4. High risk features (any one the following):
* Age \> 40 years
* Later surgical repair:
i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD
* Sinus venosus defect
* Primum defect
* WHO functional class \> 1
* Atrial fibrillation or flutter
5. Echocardiographic evidence of high risk features. Any one of the following:
* Degree of TR that is mild or greater
* Right ventricular (RV) systolic dysfunction
* Evidence of RV dilatation: Any one of the following:
i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter \> 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole \> 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)
* Any abnormality in the motion of the inter-ventricular septum
6. Ability and desire to execute the consent for follow up
Inclusion Criteria: Cohort 2 (current high risk)
1. Male and female adults (≥ 18 years of age)
2. Patients with documented history (at least one year) of an isolated, repaired congenital heart defect such as ASD, VSD, PDA, AVC (AVSD)
3. Current (within the last 12 months) evidence of 1 or more of the 7 following criteria:
* Desaturation on exercise (92% or less)
* 6 MWD \<380 m
* PFT demonstrating DLC \<70% predicted \& FEV1\>70% predicted
* ECG demonstrating i) RAD and ii) RVH or RAE
* Physical findings of edema accompanied by elevated JVP and +HJR
* CXR evidence of enlarged main and/or hilar pulmonary arterial shadows in association with right ventricular enlargement
* Elevated biomarks (BNP or NT-proBNP above upper limit of normal)
4. High risk features (any one of the following:)
* Age \> 40 years
* Later surgical repair:
i. ≥ 2 years of age for PDA or VSD ii. ≥ 1 year of age for AVC iii. ≥ 10 years of age for ASD
* Sinus venosus defect
* Primum defect
* WHO functional class \> 1
* Atrial fibrillation or flutter
5. Echocardiographic evidence of high risk features. Any one of the following:
* Degree of TR that is mild or greater
* Right ventricular (RV) systolic dysfunction
* Evidence of RV dilatation: Any one of the following:
i. Evidence of RV dilation by general, qualitative assessment ii. RV end diastolic diameter \> 3.2 cm on apical 4 chamber view at the tips of the tricuspid valve iii. RV to LV ratio at end-diastole \> 0.6 (RV and LV end diastolic dimensions measured from apical 4 chamber view, 1 cm apical of the respective valve annuli)
* Any abnormality in the motion of the inter-ventricular septum
6. Ability and desire to execute the consent for follow up
Gender
All
Gender Based
false
Keywords
Congenital Heart Disease
Pulmonary Arterial Hypertension
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Minimum Age
18 Years
NCT Id
NCT01659411
Org Class
Industry
Org Full Name
Actelion
Org Study Id
AC-052-433
Overall Status
Completed
Primary Completion Date
Primary Completion Date Type
Actual
Official Title
Adult Congenital Heart Disease Quality Enhancement Research Initiative
Primary Outcomes
Outcome Description
outcome measure: clinical outcomes: Assessment of function status, medications, and laboratory results, as well as an evaluation of medical history, physical examination, ECG, and echocardiography, in adult congenital heart disease patients at risk for pulmonary hypertension.
Outcome Measure
To characterize the clinical course in a cohort of adult patients with repaired CHD at risk for developing PAH
Outcome Time Frame
screening (visit 1) through end of study (3 years)
Secondary Ids
Secondary Id
CHRC2011-ACHD001
Secondary Outcomes
Outcome Description
outcome measure: clinical rate: To assess the rate of newly diagnosed pulmonary arterial hypertension in a cohort of adults with repaired congenital heart disease at risk for pulmonary arterial hypertension. To also compare clinical outcomes in patients who do and do not meet prespecified echocardiography criteria for suspected pulmonary arterial hypertension.
Outcome Time Frame
screening (visit 1) through end of study (3 years)
Outcome Measure
To characterize the clinical outcomes in a cohort of adult patients with repaired CHD at risk for developing PAH
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Estimated
First Submit Date
First Submit QC Date
Study Population
Adult CHD patients meeting inclusion and exclusion criteria may be enrolled
Std Ages
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
999
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Ali Zaidi
Investigator Email
azaidi@montefiore.org
Investigator Phone